NRXSHealthcare · BiotechnologyThe 2 Wall Street analysts covering NeurAxis, Inc. hold a median 12-month price target of $11 — +91.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 54 of 100 as at 10 Sept 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores NeurAxis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (84): The shares have been drifting up relative to others.
Quality (29): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on NRXS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +91.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Mar 2026 | Craig-Hallum | Maintains | Buy | — |
| 22 Dec 2025 | Craig-Hallum | Maintains | Buy | — |
| 16 June 2025 | Craig-Hallum | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NRXS appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, NeurAxis, Inc. returned +137.2% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 12% of US stocks
Cheaper than 9% of US stocks
Cheaper than 83% of US stocks
Higher than 94% of US stocks
Higher than 85% of US stocks
Higher than 94% of US stocks
Higher than 13% of US stocks
Higher than 4% of US stocks
Higher than 10% of US stocks
Higher than 7% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
NeurAxis, Inc. has a market value of $72.0M and an enterprise value of $63.9M.
Revenue in the twelve months to 30 June 2026: $5.3M. The latest quarter grew 115.7% year on year.
Net income over the same four quarters: −$7.7M, a −144.4% net margin.
Free cash flow in the twelve months to 30 June 2026: −$5.7M.
Trailing P/E: −6.0×; forward P/E: −21.0× — the forward figure prices analyst consensus estimates, not reported earnings.
NeurAxis, Inc. employs 24 people — $222K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own NeurAxis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research published a piece titled "Is Kodak having a 'Kodak moment?' 2 watchlist stocks," in which it highlights KODK and NRXS as companies worth watching for their growth.
Why it matters — The article brings NRXS to investors' attention as a growth-watch candidate alongside Kodak, potentially increasing visibility for the company.
NeurAxis reported record second-quarter 2026 revenues, driven by stronger IB-Stim demand, higher pricing, and an improved reimbursement mix that lifted gross margin. Despite the revenue surge, the NRXS stock dipped after the earnings report.
Why it matters — A NRXS watcher would care because the record revenues and higher gross margin signal improved underlying commercial performance for the company's IB-Stim business despite the post-earnings share dip.
Seeking Alpha published the transcript of NeurAxis, Inc.'s (NRXS) Q2 2026 earnings call, covering the company's quarterly financial results and management discussion.
Why it matters — A NRXS watcher would care because the earnings call transcript provides direct insight into the company's Q2 2026 performance and management's commentary on its operations.
NeurAxis announced additional medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing over 500,000 covered lives. The coverage will expand incremental access to IB-Stim treatment for beneficiaries in the Mid-Atlantic region.
Why it matters — Expanded payer coverage broadens potential patient access to NeurAxis's IB-Stim treatment in a new region.
NeurAxis announced it will report its second quarter 2026 financial results before market open on Tuesday, August 11, 2026, and will host a conference call at 9:00 am ET that same day to review the results and provide a business update.
Why it matters — Investors monitoring NRXS will gain insight into the company's recent financial performance and operational progress during the quarterly update call.
The 2 Wall Street analysts covering NeurAxis, Inc. have a median 12-month price target of $11, with estimates ranging from $9 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering NeurAxis, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NeurAxis, Inc. 54 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 10 Sept 2026, NeurAxis, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (84 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +91.6% from the last close, and Ticker Nerd's factor model ranks NeurAxis, Inc. 54 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering NeurAxis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NRXS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $13 over the next 12 months.
NeurAxis, Inc. returned +137.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
NeurAxis, Inc. is a medical technology company focused on neuromodulation therapies for chronic and debilitating conditions, with an emphasis on disorders of the gut-brain interaction.
The most recent item we track (Zacks Investment Research, 12 Sept 2026): "Is Kodak having a "Kodak moment?" 2 watchlist stocks.". Zacks Investment Research published a piece titled "Is Kodak having a 'Kodak moment?' 2 watchlist stocks," in which it highlights KODK and NRXS as companies worth watching for their growth.
NeurAxis, Inc. is a medical technology company focused on neuromodulation therapies for chronic and debilitating conditions, with an emphasis on disorders of the gut-brain interaction. Its current product portfolio centers on IB-Stim, a drug-free, non-surgical device worn behind the ear and designed to deliver percutaneous electrical nerve field stimulation for patients with functional abdominal pain associated with irritable bowel syndrome, functional dyspepsia, and related nausea symptoms. The company serves pediatric and adult patients through healthcare settings such as hospitals and clinics, where its therapies are used to support symptom management in targeted gastrointestinal conditions. NeurAxis also works to commercialize evidence-based devices that address unmet needs in digestive health and related neuromodulation care. Headquartered in Carmel, Indiana, NeurAxis operates as a specialized player in the medical device market with a focus on non-invasive treatment options.
CEO Mr. Brian Carrico · 24 employees · United States · https://neuraxis.com
